metformin has been researched along with Acute Coronary Syndrome in 15 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Acute Coronary Syndrome: An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin-associated lactic acidosis (MALA) is a rare but life-threatening condition." | 8.12 | A patient with severe metformin-associated lactic acidosis complicated by acute coronary syndrome: a case report. ( Ahmed, A; Gudowski, C; Mammadova, N; Pliquett, RU; Shkodivskyi, P; Soukup, J, 2022) |
| "Liraglutide seems to reduce GV in the acute phase of acute coronary syndrome, and patients achieved optimal control with a low incidence of hypoglycemia." | 7.96 | Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study. ( Arnau Vives, MA; Ballesteros Martin-Portugués, A; Catalá Gregori, A; Caudet Esteban, J; Cerveró Rubio, A; Del Olmo-García, MI; Hervás Marín, D; Merino-Torres, JF; Penalba Martínez, M, 2020) |
| "No randomized controlled trials evaluating metformin therapy efficacy in patients with type 2 diabetes mellitus (DM) and acute coronary syndrome (ACS) have been reported." | 7.91 | Metformin was associated with lower all-cause mortality in type 2 diabetes with acute coronary syndrome: A Nationwide registry with propensity score-matched analysis. ( Chen, KY; Chong, JT; Hsieh, IC; Hsieh, MY; Hsu, CN; Jong, CB; Lai, CL; Lin, WS; Shyu, KG; Su, FY; Ueng, KC; Voon, WC; Wu, CC, 2019) |
| "Patients with type 2 diabetes and recent acute coronary syndrome were randomized to alogliptin or placebo and standard of care." | 5.27 | Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial. ( Bergenstal, RM; Cannon, CP; Heller, SR; Howitt, H; Khunti, K; White, WB, 2018) |
| "Metformin-associated lactic acidosis (MALA) is a rare but life-threatening condition." | 4.12 | A patient with severe metformin-associated lactic acidosis complicated by acute coronary syndrome: a case report. ( Ahmed, A; Gudowski, C; Mammadova, N; Pliquett, RU; Shkodivskyi, P; Soukup, J, 2022) |
| "Liraglutide seems to reduce GV in the acute phase of acute coronary syndrome, and patients achieved optimal control with a low incidence of hypoglycemia." | 3.96 | Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study. ( Arnau Vives, MA; Ballesteros Martin-Portugués, A; Catalá Gregori, A; Caudet Esteban, J; Cerveró Rubio, A; Del Olmo-García, MI; Hervás Marín, D; Merino-Torres, JF; Penalba Martínez, M, 2020) |
| "In patients with T2DM, SGLT2i as first-line treatment may be associated with decreased events of heart failure hospitalization, acute coronary syndrome, and all-cause mortality, compared with metformin as first-line treatment." | 3.96 | Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study. ( Chang, CH; Chen, DY; Chen, SW; Chen, TH; Chu, PH; Li, YR; Lin, YS; Mao, CT; Sun, CC; Wu, M; Wu, VC, 2020) |
| "No randomized controlled trials evaluating metformin therapy efficacy in patients with type 2 diabetes mellitus (DM) and acute coronary syndrome (ACS) have been reported." | 3.91 | Metformin was associated with lower all-cause mortality in type 2 diabetes with acute coronary syndrome: A Nationwide registry with propensity score-matched analysis. ( Chen, KY; Chong, JT; Hsieh, IC; Hsieh, MY; Hsu, CN; Jong, CB; Lai, CL; Lin, WS; Shyu, KG; Su, FY; Ueng, KC; Voon, WC; Wu, CC, 2019) |
| "Higher risks for death (overall and due to cardiovascular disease) and heart failure were found for rosiglitazone compared to pioglitazone." | 3.77 | Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data. ( Gallagher, AM; Leufkens, HG; Seabroke, S; Smeeth, L; van Staa, TP, 2011) |
| "The DARE study shows that, in type 2 diabetes, good glycemic control during CR is an independent factor associated with gain in VO2 peak." | 2.80 | Influence of glycemic control on gain in VO2 peak, in patients with type 2 diabetes enrolled in cardiac rehabilitation after an acute coronary syndrome. The prospective DARE study. ( Bertrand, JH; Catargi, B; Douard, H; Feige, JM; Fischbach, M; Iliou, MC; Patois-Vergès, B; Simoneau-Robin, I; Vergès, B, 2015) |
| "Metformin was associated with younger age (p=0." | 1.62 | Use of Metformin and Platelet Reactivity in Diabetic Patients Treated with Dual Antiplatelet Therapy. ( Aimaretti, G; Caputo, M; Ceccon, C; De Luca, G; Pergolini, P; Rolla, R; Suryapranata, H; Verdoia, M, 2021) |
| "The effects of type 2 diabetes mellitus (T2DM) medications on secondary prevention after acute coronary syndrome (ACS) remain unclear." | 1.56 | Recurrent cardiovascular events in patients with newly diagnosed acute coronary syndrome: Influence of diabetes and its management with medication. ( Asano, T; Komaru, Y; Suzuki, L; Takeuchi, T; Urayama, KY, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 6 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mammadova, N | 1 |
| Soukup, J | 1 |
| Shkodivskyi, P | 1 |
| Gudowski, C | 1 |
| Ahmed, A | 1 |
| Pliquett, RU | 1 |
| Komaru, Y | 1 |
| Takeuchi, T | 1 |
| Suzuki, L | 1 |
| Asano, T | 1 |
| Urayama, KY | 1 |
| Del Olmo-García, MI | 1 |
| Hervás Marín, D | 1 |
| Caudet Esteban, J | 1 |
| Ballesteros Martin-Portugués, A | 1 |
| Cerveró Rubio, A | 1 |
| Arnau Vives, MA | 1 |
| Catalá Gregori, A | 1 |
| Penalba Martínez, M | 1 |
| Merino-Torres, JF | 1 |
| Wróbel, M | 1 |
| Rokicka, D | 1 |
| Zdrojewski, T | 1 |
| Gierlotka, M | 1 |
| Gąsior, M | 1 |
| Strojek, K | 1 |
| Chen, TH | 1 |
| Li, YR | 1 |
| Chen, SW | 1 |
| Lin, YS | 1 |
| Sun, CC | 1 |
| Chen, DY | 1 |
| Mao, CT | 1 |
| Wu, M | 1 |
| Chang, CH | 1 |
| Chu, PH | 1 |
| Wu, VC | 1 |
| White, WB | 1 |
| Heller, SR | 1 |
| Cannon, CP | 1 |
| Howitt, H | 1 |
| Khunti, K | 1 |
| Bergenstal, RM | 1 |
| Verdoia, M | 1 |
| Pergolini, P | 1 |
| Rolla, R | 1 |
| Ceccon, C | 1 |
| Caputo, M | 1 |
| Aimaretti, G | 1 |
| Suryapranata, H | 1 |
| De Luca, G | 1 |
| Jong, CB | 1 |
| Chen, KY | 1 |
| Hsieh, MY | 1 |
| Su, FY | 1 |
| Wu, CC | 1 |
| Voon, WC | 1 |
| Hsieh, IC | 1 |
| Shyu, KG | 1 |
| Chong, JT | 1 |
| Lin, WS | 1 |
| Hsu, CN | 1 |
| Ueng, KC | 1 |
| Lai, CL | 1 |
| Leibovitz, E | 1 |
| Gottlieb, S | 1 |
| Goldenberg, I | 1 |
| Gevrielov-Yusim, N | 1 |
| Matetzky, S | 1 |
| Gavish, D | 1 |
| Vergès, B | 1 |
| Patois-Vergès, B | 1 |
| Iliou, MC | 1 |
| Simoneau-Robin, I | 1 |
| Bertrand, JH | 1 |
| Feige, JM | 1 |
| Douard, H | 1 |
| Catargi, B | 1 |
| Fischbach, M | 1 |
| Zghebi, SS | 1 |
| Steinke, DT | 1 |
| Rutter, MK | 1 |
| Emsley, RA | 1 |
| Ashcroft, DM | 1 |
| Alonso-García, A | 1 |
| García-Soidán, FJ | 1 |
| Lisbona-Gil, A | 1 |
| Gallagher, AM | 1 |
| Smeeth, L | 1 |
| Seabroke, S | 1 |
| Leufkens, HG | 1 |
| van Staa, TP | 1 |
| Serebruany, VL | 1 |
| Atar, D | 1 |
| García-Moll, X | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome[NCT00968708] | Phase 3 | 5,380 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Effect of Strict Glycemic Control on Improvement of Exercise Capacities (VO2 Peak, Peak Workload After Cardiac Rehabilitation, in Patients With Type 2 Diabetes Mellitus With Coronary Artery Disease.[NCT00354237] | 60 participants (Actual) | Interventional | 2005-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary Major Adverse Cardiac Events were defined as a composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 11.8 |
| Alogliptin | 11.3 |
Secondary MACE composite consisted of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or urgent revascularization due to unstable angina; these events were adjudicated by an independent cardiovascular endpoint committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-of date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 13.4 |
| Alogliptin | 12.7 |
2 trials available for metformin and Acute Coronary Syndrome
| Article | Year |
|---|---|
Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy | 2018 |
Influence of glycemic control on gain in VO2 peak, in patients with type 2 diabetes enrolled in cardiac rehabilitation after an acute coronary syndrome. The prospective DARE study.
Topics: Acute Coronary Syndrome; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Exercise Therapy; Female; F | 2015 |
13 other studies available for metformin and Acute Coronary Syndrome
| Article | Year |
|---|---|
A patient with severe metformin-associated lactic acidosis complicated by acute coronary syndrome: a case report.
Topics: Acidosis, Lactic; Acute Coronary Syndrome; Acute Kidney Injury; Bicarbonates; Diabetes Mellitus, Typ | 2022 |
Recurrent cardiovascular events in patients with newly diagnosed acute coronary syndrome: Influence of diabetes and its management with medication.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; F | 2020 |
Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study.
Topics: Acute Coronary Syndrome; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobi | 2020 |
Metformin and cardiac injury after acute coronary syndrome in diabetic patients with no history of cardiovascular disease: data from the PL-ACS registry.
Topics: Acute Coronary Syndrome; Cardiovascular Diseases; Diabetes Mellitus; Humans; Metformin; Registries | 2020 |
Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study.
Topics: Acute Coronary Syndrome; Adult; Aged; Cardiovascular Diseases; Databases, Factual; Diabetes Mellitus | 2020 |
Use of Metformin and Platelet Reactivity in Diabetic Patients Treated with Dual Antiplatelet Therapy.
Topics: Acute Coronary Syndrome; Adult; Aged; Blood Platelets; Comorbidity; Diabetes Mellitus; Dual Anti-Pla | 2021 |
Metformin was associated with lower all-cause mortality in type 2 diabetes with acute coronary syndrome: A Nationwide registry with propensity score-matched analysis.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hypogly | 2019 |
Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS).
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hypogly | 2013 |
Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Cardiovascular Diseases; Cohort Studies; Diabetes M | 2016 |
[Treatment guidelines for hyperglycaemia in type 2 diabetes patients with stable chronic heart failure or ischemic cardiomyopathy without heart failure].
Topics: Acute Coronary Syndrome; Algorithms; Consensus; Contraindications; Diabetes Mellitus, Type 2; Drug T | 2010 |
Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Databases | 2011 |
Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?
Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Co | 2012 |
[Inflammation, atherosclerosis, classic cardiovascular risk factors, biostatistics, clinical significance. Where are we?].
Topics: Acute Coronary Syndrome; Atherosclerosis; Biometry; Dyslipidemias; Fluorobenzenes; Humans; Hydroxyme | 2007 |